Korean Red Ginseng Regulates Intestinal Tight Junction and Inflammation in the Colon of a Parkinson's Disease Mouse Model

J Med Food. 2020 Dec;23(12):1231-1237. doi: 10.1089/jmf.2019.4640. Epub 2020 Oct 29.

Abstract

Recent studies have determined that gastrointestinal function contributes to the control of Parkinson's disease (PD). Gastrointestinal dysfunction results in a leaky intestinal barrier, inducing inflammation in the gut. Korean red ginseng (KRG) is widely used for the treatment of numerous afflictions, including inflammation and neurodegenerative disease. We investigated changes in the intestinal tight junctions and proinflammatory cytokines in the colon, and alpha-synuclein (aSyn) in the colon and the substantia nigra (SN) of a PD mouse model. Eight-week-old male C57BL/6 mice were intraperitoneally administered 30 mg/kg of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) once a day for 5 days, and orally given 100 mg/kg of KRG for 12 consecutive days. Alterations in the levels of occludin, zonula occludens-1 (ZO-1), tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) in the colon, and the expressions of aSyn and tyrosine hydroxylase (TH) in the colon and the SN were evaluated. Oral administration of KRG significantly prevents the MPTP-induced motor dysfunction, and suppresses the MPTP-induced disruption of occludin and ZO-1, and suppresses the increase in TNF-α and IL-1β in the colon of mice. In addition, KRG prevents accumulation of aSyn and TH in the colon and the SN. These results suggest that KRG has the potential to prevent MPTP-induced leaky gut barrier, inflammation, and accumulation of aSyn.

Keywords: Korean red ginseng; Parkinson's disease; alpha-synuclein; inflammation; tight junction.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Colon / drug effects*
  • Colon / metabolism
  • Disease Models, Animal
  • Inflammation / drug therapy
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Panax / chemistry*
  • Parkinson Disease* / drug therapy
  • Plant Preparations / therapeutic use*
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism
  • Tight Junctions / drug effects*
  • alpha-Synuclein / metabolism

Substances

  • Plant Preparations
  • alpha-Synuclein
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine